Full Press Release Details
Cytori Provides Twelve Month Data Update on Scleradec-I Trial
SAN DIEGO Cytori Therapeutics, Inc.
(NASDAQ: CYTX) announced today preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. B. Granel and Prof. G. Magalon from the Assistance Publique des H pitaux de Marseille.
In the previously published six month follow-up data, Cytori s ECCS-50 therapeutic showed:
The manuscript describing these data in detail can be viewed at http://ard.bmj.com/content/early/2014/08/10/annrheumdis-2014-205681.long.
A preliminary assessment for 12 month follow-up data has been reviewed by the Company which management believes reflects:
The investigators have prepared and submitted for publication a scientific manuscript based on final 12 month
data. Once this manuscript has been accepted for publication and a publication date announced, Cytori will provide an update to investors.
Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a
variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell
Therapy may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori s proprietary technologies and products. For more information: visit www.cytori.com.
Cytori Therapeutics, Inc.